Tirzepatide Shows Lower Cardiovascular Risk Compared to Dulaglutide in Type 2 Diabetes
New findings published in Diabetes Care highlight meaningful differences in cardiovascular outcomes among commonly prescribed diabetes therapies. Researchers found that tirzepatide—marketed as Mounjaro—was associated with a lower risk of major cardiovascular events compared to dulaglutide (Trulicity) in adults with type 2 diabetes and existing cardiovascular disease. The study analyzed real-world data from a large national database, comparing outcomes across multiple GLP-1–based therapies. While tirzepatide demonstrated a reduced rate of cardiovascular events versus dulaglutide, researchers found…
Read Full Article